Q: hello 5i team
GILD is down 10% for the month. it appears reasons given as per the info i can find are;
slowing prescription sales on the hep C drugs
a 4 BB debt offering in Nov which investors didnčt like even though it appears to be money raised to repay existing debt
and there has been some modest insider selling
I am keenly interested in this company as it appears according to reports, Gilead - which has from what I can see the only effective Hep C drug on the market at this time - has treated a mere 3% of the US's total pool of HCV patients. Plus, am I wrong in thinking that insurers will have to include the GILD Hep C treatment drugs on their approved list sooner rather than later
With this info and any other you may have at your disposal, what would you recommend... buy, hold or sell.
Thanks for all you do
Gord
GILD is down 10% for the month. it appears reasons given as per the info i can find are;
slowing prescription sales on the hep C drugs
a 4 BB debt offering in Nov which investors didnčt like even though it appears to be money raised to repay existing debt
and there has been some modest insider selling
I am keenly interested in this company as it appears according to reports, Gilead - which has from what I can see the only effective Hep C drug on the market at this time - has treated a mere 3% of the US's total pool of HCV patients. Plus, am I wrong in thinking that insurers will have to include the GILD Hep C treatment drugs on their approved list sooner rather than later
With this info and any other you may have at your disposal, what would you recommend... buy, hold or sell.
Thanks for all you do
Gord